# Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

> **NCT06833411** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 178 (estimated)

## Conditions studied

- Giant Cell Arteritis (GCA)

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06833411
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-08
- **Final completion:** 2032-08
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833411, "Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06833411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*